ImageneBio Q1 net loss $10.6M; cash $117.2M, raised $30M in April private placement

ImageneBio, Inc.

2026-Q1 EPS reported -$0.95

Net loss of $10.6M for Q1 2026, vs $9.1M in Q1 2025; R&D $6.0M, G&A $6.1M.
Cash of $117.2M as of March 31; April private placement raised $30M, extending runway into Q1 2028.
Phase 2b ADAPTIVE trial in AD advancing under amended protocol; topline data anticipated Q4 2027.
Plan to initiate Phase 2 in alopecia areata in 2026; initial data expected 2028, based on proof-of-concept.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-211935
form_type: 8-K
ticker: IMA
cik: 0001835579
company_name: ImageneBio, Inc.
filed_at: 2026-05-07T23:59:59+00:00
discovered_at: 2026-05-14T18:02:33.071042+00:00
generated_at: 2026-05-14T22:00:44.446014+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-211935
json_url: https://secwatch.observer/filing/0001193125-26-211935.json
markdown_url: https://secwatch.observer/filing/0001193125-26-211935.md
text_url: https://secwatch.observer/filing/0001193125-26-211935.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312526211935/0001193125-26-211935-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312526211935/d151394d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-211935

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.